VKV. Kerner

V. Kerner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


V. Kerner has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Major haemorrhage: past, present and future

    by A. Shah, V. Kerner, S. J. Stanworth, S. Agarwal

    Summary: Major haemorrhage is a leading cause of morbidity and mortality worldwide. Successful treatment requires early recognition, planned responses, readily available resources (such as blood products) and rapid access to surgery or interventional radiology. Major haemorrhage is often accompanied by volume loss, haemodilution, acidaemia, hypothermia and coagulopathy (factor consumption and fibrinolysis). Management of major haemorrhage over the past decade has evolved to now deliver a ‘package’ of haemostatic resuscitation including: surgical or radiological control of bleeding; regular monitoring of haemostasis; advanced critical care support; and avoidance of the lethal triad of hypothermia, acidaemia and coagulopathy. Recent trial data advocate for a more personalised approach depending on the clinical scenario. Fresh frozen plasma should be given as early as possible in major trauma in a 1:1 ratio with red blood cells until the results of coagulation tests are available. Tranexamic acid is a cheap, life‐saving drug and is advocated in major trauma, postpartum haemorrhage and surgery, but not in patients with gastrointestinal bleeding. Fibrinogen levels should be maintained > 2 g.l −1 in postpartum haemorrhage and > 1.5 g.l −1 in other haemorrhage. Improving outcomes after major traumatic haemorrhage is now driving research to include extending blood‐product resuscitation into prehospital care.


  • Open Access

    Fifty liver transplants: a single centre experience of haemodynamic management in liver transplantation for cirrhosis [part 2]

    by B. Gunetilleke, R. Ranamuni, D. Jayaweera, N. Welikala, V. Kerner, N. Munasinghe, N. Wickremasinghe, R. Withanage, S. Hewage, N. Wijesuriya, et al.

    Globally, an estimated one million deaths occur annually due to complications of cirrhosis. Cirrhosis with end stage liver disease [ESLD] is a leading cause death due to noncommunicable diseases in Sri Lanka. Non-alcoholic fatty liver disease [NAFLD] and alcohol related liver disease [ARLD] are the principal causes of ESLD due to cirrhosis in Sri Lanka. Liver transplantation remains the only curative treatment for such patients. Multiorgan dysfunction and hemodynamic instability characteristic of ESLD adds to the complexity of perioperative care in liver transplantation. Maintenance of stable hemodynamics including optimal hemostasis forms the core of the anaesthetic strategy in liver transplantation.


  • Open Access

    Fifty liver transplants: a single centre experience of haemodynamic management in liver transplantation for cirrhosis [part 1]

    by B. Gunetilleke, R. Ranamuni, D. Jayaweera, N. Welikala, V. Kerner, N. Munasinghe, R. Withanage, N. Wickremasinghe, S. Hewage, N. Wijesuriya, et al.

    Cirrhosis with end stage liver disease (ESLD) is a leading cause of non-communicable disease related deaths in Sri Lanka. Liver transplantation is the only curative treatment for patients with ESLD. The complex multisystem involvement and unique cardiovascular profile characteristic of ESLD present formidable challenges during liver transplantation. Management of the rapid and varied hemodynamic changes during surgery requires an in depth understanding of the physiological effects of each intervention. Based on the current literature and the experience gained at our center during the management of 50 liver transplants, we present optimization strategies and perioperative hemodynamic interventions which we use to ‘Fast track’ recovery following liver transplantation.